Thelansis’s “Gorlin Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gorlin Syndrome treatment options for eight major markets (United States, Germany, France, Italy, Spain, UK, Japan, and China).
The Gorlin syndrome market is small but concentrated. Today, spend comes from off-label and repurposed options: surgical care, topicals and procedures, and the hedgehog inhibitors vismodegib and sonidegib, which are approved for advanced BCC rather than for Gorlin syndrome itself. The report sizes the 2026 market across the G8 (US, EU5, Japan, China) by country, drug class, and line of therapy. Our patient-based, bottom-up forecast runs from the diagnosed prevalent pool through the drug-treated population, line of therapy, uptake and net price, with a top-down cross-check validating each output. The forecast shows how a first Gorlin-specific preventive therapy could change market structure from 2026 to 2036.
Revenue is driven by the first approval of a Gorlin-specific therapy and by the shift from reactive tumor removal toward prevention. Slower or limited uptake would constrain it. The outlook covers launch timing and the impact of pivotal outcomes. It also covers pricing and reimbursement in a rare-disease population, and the range of scenarios built into the model.
Gorlin syndrome is an autosomal dominant condition, most often caused by PTCH1 variants. It predisposes patients to multiple basal cell carcinomas (BCCs), usually from adolescence or early adulthood. It also causes odontogenic keratocysts, palmar/plantar pits, skeletal and ocular abnormalities, and an increased risk of medulloblastoma, particularly with SUFU variants. Some patients develop only a few BCCs, while others develop hundreds or more over a lifetime. The result is repeated surgeries, cumulative scarring and a lifelong need for surveillance across dermatology, oncology, dental, genetics, and neurology.
Published prevalence estimates range from roughly 1 in 31,000 to 1 in 164,000, depending on geography and methodology. The report provides country-level incidence, prevalent, diagnosed, drug-treatable and drug-treated populations for 2026-2036 across the G8. Epidemiology for up to 31 countries is available in the Thelansis knowledge database. In the US 2026, Thelansis has projected ~17,790 prevalent cases, ~13,876 diagnosed & 162 incident diagnosed cases.
Patients are segmented by:
No drug is currently approved specifically for Gorlin syndrome. Management relies on surgery and procedural options, topicals (imiquimod, 5-FU), photodynamic therapy, retinoids, and the hedgehog inhibitors Erivedge (vismodegib) and Odomzo (sonidegib). PD-1 inhibitors are used in later lines for advanced disease.
The report maps the patient journey from first presentation (often jaw cysts or early BCCs) through genetic confirmation, surveillance and first-line to fourth-line management. It includes region-specific differences across the G8.
Covers hedgehog pathway (SMO) inhibitors, topical immunomodulators and cytotoxics, photodynamic therapy, retinoids, immune checkpoint inhibitors and emerging modalities.
Includes topical hedgehog inhibition (SGT-610/patidegib), other topical and repurposed agents in development, and early-stage approaches such as locally injectable options for odontogenic keratocysts.
Key gaps are the lack of an approved preventive therapy, hedgehog inhibitor side effects that limit long-term use, no approved option addressing non-BCC manifestations, and the high cumulative surgical burden. Access to genetic testing and multidisciplinary care is also uneven across countries.
The standard of care is moving from reactive management (excision, Mohs, cryotherapy, imiquimod, 5-FU, PDT, radiation avoided where possible) toward targeted and preventive approaches. Systemic hedgehog inhibitors reduce tumor burden but are limited by tolerability. This is pushing development toward topical and locally delivered options with better safety.
These include a first preventive therapy, new options for keratocysts and other manifestations, label expansion into high-frequency BCC, earlier pediatric and young-adult intervention, and genotype-guided care.
The report reviews pivotal and mid-stage programs, including endpoint design, comparators, and efficacy and safety outcomes. The most closely watched is Sol-Gel's global, randomized, double-blind, vehicle-controlled Phase 3 of SGT-610 (patidegib gel 2%). It enrolled 113 adults, of whom 102 completed 12 months of twice-daily facial application. Its endpoint is the number of new BCCs on the face. The last patient visit has been completed, and top-line results are expected in late November 2026. We will update the report content and forecast model with the readout.
Interviews with dermatologists, medical oncologists, geneticists and Gorlin syndrome specialists cover the clinically meaningful efficacy threshold, the safety and tolerability needed for chronic use, expectations for target product profiles, and views on pricing and reimbursement across the United States, EU5, Japan, and China.
Covers the factors likely to shape uptake: strength of the efficacy signal, safety, convenience of use, payer acceptance, specialist awareness, and how much of the patient pool a therapy could realistically reach.
Hedgehog pathway inhibitors, topical therapies, surgical interventions, radiotherapy, immunotherapy and other emerging targeted therapies, with 2026 and 2036 share.
By genotype, tumor burden, age cohort and disease severity.
First- to fourth-line patient and revenue pools, including relapsed and refractory populations.
Country-level views for the United States, Germany, France, Italy, Spain, the UK, Japan and China, plus regional views for Asia Pacific, Europe, North America, the Middle East, Africa and Latin America. Additional countries can be added to the dashboard on request.
The forecast follows the Thelansis funnel: population → incidence → prevalence → diagnosed → drug-treatable → drug-treated → target patients → patients on product. Persistence, compliance and dosing then convert patients to volume, and pricing and reimbursement convert volume to sales.
Uptake is modeled using analog, attribute and conjoint-based approaches. The model includes cannibalization, event-impact analysis, patent-expiry and erosion curves, and scenario and sensitivity analysis. All assumptions and sources are documented.
Secondary research draws on peer-reviewed literature, registries, regulatory and HTA sources, trial registries and company disclosures. Primary research includes in-depth interviews with physicians and payers on our panel, with Gorlin interviews conducted during 2025–2026.
Bottom-up forecasts are validated against a top-down view. Epidemiology is cross-checked against published benchmarks and population denominators, and outputs are reconciled across the patient funnel before release. We incorporate the latest updates before each release.
Includes Report (PDF), Epidemiology model (Excel), Market forecast model (Excel), along with regular updates, customization, and consultant support.
G8 Markets (US, EU5, Japan, and China) and Global/Top 30 Markets (US, Germany, France, Italy, Spain, UK, Japan, China, Canada, Australia, South Korea, India, Saudi Arabia, UAE, Netherlands, Switzerland, Sweden, Denmark, Norway, Finland, Belgium, Austria, Ireland, Poland, Turkey, Russia, Mexico, Brazil, Argentina, New Zealand, and Singapore).
| Included | |||
|---|---|---|---|
| Interactive Excel epidemiology model | |||
| Excel market forecast model with dashboard | – | ||
| Full analyst report (PowerPoint) | – | – |
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Get Figure 1 unblurred, with the scope and sample pages of this report, by email.
Your information is secure and confidential.
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Test Report Second report
Our team will get in touch with you shortly about the Test Report Second report.